Sindet-Pedersen, Caroline
Pallisgaard, Jannik Langtved
Staerk, Laila
Berger, Jeffrey S.
Lamberts, Morten
Torp-Pedersen, Christian
Gislason, Gunnar H.
Olesen, Jonas Bjerring
Article History
Received: 8 February 2017
Accepted: 2 May 2017
First Online: 13 June 2017
Competing Interests
: The Danish council of independent research supported this study (No.: 4183-00008). G.G. is supported by an unrestricted clinical research scholarship from the Novo Nordisk Foundation. The funder had no influence on the study design, interpretation of results, or the decision to submit the manuscript for publication. L.S. has received funding for research from Boehringer Ingelheim. J.L.P.: has received funding for research from Boehringer Ingelheim and Bayer. C.T.P.: declares research contracts with Bayer and Biotronic and speaker fees for Bayer and BMS. G.G.: has received funding for research from Boehringr Ingelheim, Pfizer, BMS, AstraZeneca and Bayer and declares ownership of stocks in Lundbeck A/S, Novo Nordisk A/S and ALK Abello pharmaceuticals. J.B.O.: has received speaker fees from Bristol-Myers Squibb, Boehringer Ingelheim, Bayer, and AstraZeneca, previous funding for research from the Lundbeck Foundation, and current funding for research from the Bristol-Myers Squibb and The Capital Region of Denmark, Foundation for Health Research. M.L. has received speaker fees from Bristol-Meyer Squibb and Bayer. J.B.: Research support from Astra Zeneca and Consultant for Merck, Astra Zeneca, and Janssen.